Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Krystal Biotech Inc's Business Segments
Krystal Biotech Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 116
Regions Reported
1
Krystal Biotech Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - Q1 FY2026
- Europe17.8%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 21 | 17.8% |
Description of Krystal Biotech Inc
Krystal Biotech Inc. is a biotechnology company based in the United States that focuses on developing and commercializing transformative gene therapies for patients suffering from debilitating skin diseases. The company's mission is to deliver effective and affordable treatment options to those affected by genetic skin disorders.
Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech was founded in 2015 by a team of scientists, entrepreneurs, and dermatologists who recognized the immense potential of gene therapy in addressing previously untreatable conditions.
The company's primary focus is on developing therapies for rare and difficult-to-treat genetic skin diseases, with their lead candidate being KB103. KB103 is a gene therapy designed to treat dystrophic epidermolysis bullosa (DEB), a genetic disorder characterized by extremely fragile skin that can tear and blister with minimal trauma. DEB currently has no cure or effective treatment, thus making KB103 a groundbreaking development in the field.
Krystal Biotech's platform technology, utilizing a non-replicating, recombinant viral vector called HSV-1, allows for the delivery and expression of functional genes directly to the patient's skin cells. This approach offers the potential for long-lasting therapeutic benefits and aims to address the root cause of the disease at the genetic level.
The company has also developed a proprietary skin delivery system called STAR-D, which stands for Skin TARgeted Delivery. STAR-D helps achieve efficient and targeted delivery of the therapeutic gene to the affected area of the skin, minimizing adverse effects and maximizing treatment efficacy.
Krystal Biotech places a strong emphasis on patient advocacy and engagement. They work closely with patient organizations and advocacy groups to ensure a deep understanding of the unmet medical needs and maintain patient-centricity in their research and development efforts.
In addition to their lead candidate KB103, Krystal Biotech has an active drug pipeline, including potential treatments for other genetic skin disorders. The company's research and development efforts are supported by a team of dedicated scientists, clinicians, and industry experts who bring together a wealth of experience in gene therapy, dermatology, and biotechnology.
Krystal Biotech has actively collaborated with academic institutions, universities, and research organizations to accelerate the development of their gene therapies. These collaborations enable access to cutting-edge technologies and expertise, further bolstering the company's scientific capabilities.
As a publicly traded company, Krystal Biotech aims to create long-term value for its shareholders while driving meaningful advancements in gene therapy. They prioritize regulatory compliance, clinical trial transparency, and robust intellectual property protection to safeguard their innovations and support sustainable growth.
Overall, Krystal Biotech Inc. is a pioneering biotechnology company with a mission to revolutionize the treatment landscape for genetic skin diseases through innovative gene therapy solutions. Through their commitment to research excellence, patient advocacy, and strategic partnerships, they aim to transform the lives of individuals suffering from debilitating conditions.
Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech was founded in 2015 by a team of scientists, entrepreneurs, and dermatologists who recognized the immense potential of gene therapy in addressing previously untreatable conditions.
The company's primary focus is on developing therapies for rare and difficult-to-treat genetic skin diseases, with their lead candidate being KB103. KB103 is a gene therapy designed to treat dystrophic epidermolysis bullosa (DEB), a genetic disorder characterized by extremely fragile skin that can tear and blister with minimal trauma. DEB currently has no cure or effective treatment, thus making KB103 a groundbreaking development in the field.
Krystal Biotech's platform technology, utilizing a non-replicating, recombinant viral vector called HSV-1, allows for the delivery and expression of functional genes directly to the patient's skin cells. This approach offers the potential for long-lasting therapeutic benefits and aims to address the root cause of the disease at the genetic level.
The company has also developed a proprietary skin delivery system called STAR-D, which stands for Skin TARgeted Delivery. STAR-D helps achieve efficient and targeted delivery of the therapeutic gene to the affected area of the skin, minimizing adverse effects and maximizing treatment efficacy.
Krystal Biotech places a strong emphasis on patient advocacy and engagement. They work closely with patient organizations and advocacy groups to ensure a deep understanding of the unmet medical needs and maintain patient-centricity in their research and development efforts.
In addition to their lead candidate KB103, Krystal Biotech has an active drug pipeline, including potential treatments for other genetic skin disorders. The company's research and development efforts are supported by a team of dedicated scientists, clinicians, and industry experts who bring together a wealth of experience in gene therapy, dermatology, and biotechnology.
Krystal Biotech has actively collaborated with academic institutions, universities, and research organizations to accelerate the development of their gene therapies. These collaborations enable access to cutting-edge technologies and expertise, further bolstering the company's scientific capabilities.
As a publicly traded company, Krystal Biotech aims to create long-term value for its shareholders while driving meaningful advancements in gene therapy. They prioritize regulatory compliance, clinical trial transparency, and robust intellectual property protection to safeguard their innovations and support sustainable growth.
Overall, Krystal Biotech Inc. is a pioneering biotechnology company with a mission to revolutionize the treatment landscape for genetic skin diseases through innovative gene therapy solutions. Through their commitment to research excellence, patient advocacy, and strategic partnerships, they aim to transform the lives of individuals suffering from debilitating conditions.
Krystal Biotech Inc. is a pioneering biopharmaceutical company that specializes in the development and commercialization of genetic medicines targeted at patients suffering from rare and serious dermatological diseases. The company utilizes a proprietary gene therapy platform designed to significantly transform the lives of patients afflicted with these debilitating conditions.
Segments:
Krystal Biotech operates primarily in the biotechnology sector, with a distinct focus on gene therapy within dermatology. The core segments of the company include:
1. Research and Development (R&D): This segment involves the continuous exploration and innovation of gene therapies aimed at treating various dermatological conditions. Krystal’s R&D efforts are dedicated to understanding the genetic underpinnings of skin diseases, identifying potential therapeutic targets, and developing effective gene delivery systems.
2. Manufacturing: Krystal Biotech emphasizes high-quality manufacturing processes to produce its gene therapy products. This segment encompasses the scale-up of production, adherence to Good Manufacturing Practices (GMP), and ensuring that all products meet the regulatory standards before reaching the market.
3. Commercialization: The commercialization segment is vital to translating research findings into available therapies for patients. This includes strategies for market entry, sales, distribution, and educating healthcare providers and patients about the benefits and applications of Krystals gene therapies.
Products:
Krystal Biotechs leading product is Beremagene Geperpavec (brand name GEM-20), a groundbreaking gene therapy targeted at dystrophic epidermolysis bullosa (DEB)— a rare genetic disorder characterized by extreme skin fragility and blistering. Key attributes of GEM-20 include:
- Mechanism of Action: GEM-20 employs an innovative gene delivery system that introduces a modified version of the COL7A1 gene into the skin cells of patients. This modified gene enables these cells to produce functional type VII collagen, a protein essential for the structural integrity of skin layers.
- Therapeutic Goals: The primary aim of GEM-20 is to mitigate the symptoms of DEB by reducing blister formation, promoting faster wound healing, and improving overall quality of life for patients. Given the rarity of DEB and lack of effective treatments, GEM-20 represents a potentially transformative option for those affected.
- Clinical Development: The product has undergone rigorous clinical trials, demonstrating its safety and efficacy. The data gathered from these trials inform both regulatory submissions and the continued evolution of therapeutic strategies.
Services:
In addition to developing its flagship product, Krystal Biotech offers a suite of services aimed at supporting the broader scope of genetic medicine development and commercialization:
1. Preclinical and Clinical Trial Development: The company engages in comprehensive preclinical research, followed by the design and execution of clinical trials that assess the safety, efficacy, and pharmacokinetics of its therapies.
2. Regulatory Affairs and Compliance: Understanding the regulatory landscape is crucial for biopharmaceutical companies. Krystal Biotech works closely with regulatory agencies to navigate the requirements for bringing gene therapies to market, ensuring compliance with all applicable laws and guidelines.
3. Manufacturing and Quality Control: The company maintains robust quality control processes to assure that all products meet the stringent quality standards required for biological products. This aspect of service ensures the consistency and reliability of their gene therapies.
4. Marketing and Distribution: An integral part of the commercialization strategy is to educate stakeholders about Krystal’s innovative gene therapies. The company collaborates with healthcare providers, industry partners, and patient advocacy groups to drive awareness and ensure that patients have access to the treatments they need.
5. Community Engagement: Krystal Biotech actively engages with healthcare professionals, patient advocacy organizations, and key opinion leaders to broaden the understanding of its gene therapies and their impacts. This involves educational initiatives and participation in industry conferences and symposiums.
Conclusion:
Krystal Biotech Inc. is dedicated to advancing the field of genetic medicine with an emphasis on addressing unmet medical needs within dermatology. Through its innovative products and comprehensive suite of services, the company aims to enhance the quality of life for patients suffering from rare and serious dermatological diseases, marking a significant progression in the landscape of treatments available for such challenging conditions. Their commitment to rigorous research, regulatory adherence, and community collaboration fuels their mission to make impactful changes in the realm of skin disease therapy.
Segments:
Krystal Biotech operates primarily in the biotechnology sector, with a distinct focus on gene therapy within dermatology. The core segments of the company include:
1. Research and Development (R&D): This segment involves the continuous exploration and innovation of gene therapies aimed at treating various dermatological conditions. Krystal’s R&D efforts are dedicated to understanding the genetic underpinnings of skin diseases, identifying potential therapeutic targets, and developing effective gene delivery systems.
2. Manufacturing: Krystal Biotech emphasizes high-quality manufacturing processes to produce its gene therapy products. This segment encompasses the scale-up of production, adherence to Good Manufacturing Practices (GMP), and ensuring that all products meet the regulatory standards before reaching the market.
3. Commercialization: The commercialization segment is vital to translating research findings into available therapies for patients. This includes strategies for market entry, sales, distribution, and educating healthcare providers and patients about the benefits and applications of Krystals gene therapies.
Products:
Krystal Biotechs leading product is Beremagene Geperpavec (brand name GEM-20), a groundbreaking gene therapy targeted at dystrophic epidermolysis bullosa (DEB)— a rare genetic disorder characterized by extreme skin fragility and blistering. Key attributes of GEM-20 include:
- Mechanism of Action: GEM-20 employs an innovative gene delivery system that introduces a modified version of the COL7A1 gene into the skin cells of patients. This modified gene enables these cells to produce functional type VII collagen, a protein essential for the structural integrity of skin layers.
- Therapeutic Goals: The primary aim of GEM-20 is to mitigate the symptoms of DEB by reducing blister formation, promoting faster wound healing, and improving overall quality of life for patients. Given the rarity of DEB and lack of effective treatments, GEM-20 represents a potentially transformative option for those affected.
- Clinical Development: The product has undergone rigorous clinical trials, demonstrating its safety and efficacy. The data gathered from these trials inform both regulatory submissions and the continued evolution of therapeutic strategies.
Services:
In addition to developing its flagship product, Krystal Biotech offers a suite of services aimed at supporting the broader scope of genetic medicine development and commercialization:
1. Preclinical and Clinical Trial Development: The company engages in comprehensive preclinical research, followed by the design and execution of clinical trials that assess the safety, efficacy, and pharmacokinetics of its therapies.
2. Regulatory Affairs and Compliance: Understanding the regulatory landscape is crucial for biopharmaceutical companies. Krystal Biotech works closely with regulatory agencies to navigate the requirements for bringing gene therapies to market, ensuring compliance with all applicable laws and guidelines.
3. Manufacturing and Quality Control: The company maintains robust quality control processes to assure that all products meet the stringent quality standards required for biological products. This aspect of service ensures the consistency and reliability of their gene therapies.
4. Marketing and Distribution: An integral part of the commercialization strategy is to educate stakeholders about Krystal’s innovative gene therapies. The company collaborates with healthcare providers, industry partners, and patient advocacy groups to drive awareness and ensure that patients have access to the treatments they need.
5. Community Engagement: Krystal Biotech actively engages with healthcare professionals, patient advocacy organizations, and key opinion leaders to broaden the understanding of its gene therapies and their impacts. This involves educational initiatives and participation in industry conferences and symposiums.
Conclusion:
Krystal Biotech Inc. is dedicated to advancing the field of genetic medicine with an emphasis on addressing unmet medical needs within dermatology. Through its innovative products and comprehensive suite of services, the company aims to enhance the quality of life for patients suffering from rare and serious dermatological diseases, marking a significant progression in the landscape of treatments available for such challenging conditions. Their commitment to rigorous research, regulatory adherence, and community collaboration fuels their mission to make impactful changes in the realm of skin disease therapy.